Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
about
Clinical implementation of pharmacogeneticsEconomic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteratureGut microbiota and tacrolimus dosing in kidney transplantationAn Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T CellsImpact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.TAC-TIC use of tacrolimus-based regimens in lupus nephritis.Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients.Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know.Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana.Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation.Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.Anellovirus loads are associated with outcomes in pediatric lung transplantation.Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus.Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.
P2860
Q28072159-C0B98EA0-72F0-4CF5-9549-ED01E04B2DE8Q28073025-80285753-107B-425D-8394-F50D39AA3E4CQ28545131-A41F0155-0DF2-4E43-8913-9BDC7D74D103Q33780582-AACE8AC9-3C3A-4DE2-9F24-E8EA5682958EQ36183911-B40AE03E-0B0B-4495-BF86-8DB2A2D5381EQ36410101-C3B68AF8-1B26-4EF1-B56A-0156FEB92F75Q36465101-A7876788-E3C6-4E7A-BEFD-DBD8BC6E236AQ37587317-E8EDC96E-AFD7-4D8F-A88F-5A2D92BC85EEQ37633166-A3873DB2-2EC1-4B6F-8EDF-0D4DD24A39EEQ38269284-49EFF38D-8F56-4B60-AB3E-55CC26F6EF43Q38329297-1EE06467-404E-4256-9FB0-AFE32589D19BQ38840168-B65D1D47-80FF-43F7-9A4B-00FD55E0637EQ38906762-416BF4EB-C0F4-4F96-9498-E70BB33DDEBBQ39041618-9152CDC7-C5E4-4D0B-8E06-1D1BC505F423Q41107159-CA766CB0-F6BC-48AF-9548-B3B5F8F0F47EQ41434713-31332BF3-4F12-4439-907F-EC5D4D21C508Q41587506-AF6C6B78-D27A-4CB4-B024-CD3FAE3214E6Q45861259-1FD09C1F-9621-4400-9AEC-BE4A05C4AD78Q47318170-6389B56C-FFF0-4DA7-842E-84C482D5ECA6Q47596410-544659D5-85B3-4A66-82B0-A313A5BF25D6Q53079716-347B0167-3C57-48C4-9E76-3975B9A5F7D4Q53478295-2F582C09-846B-4ACF-8BE1-038CDC9F6DBFQ55129457-5A17BD99-BF00-4EE9-91A0-2A0F93BC951A
P2860
Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetic considerations ...... and kidney transplant patients
@en
Pharmacogenetic considerations ...... nd kidney transplant patients.
@nl
type
label
Pharmacogenetic considerations ...... and kidney transplant patients
@en
Pharmacogenetic considerations ...... nd kidney transplant patients.
@nl
prefLabel
Pharmacogenetic considerations ...... and kidney transplant patients
@en
Pharmacogenetic considerations ...... nd kidney transplant patients.
@nl
P2093
P2860
P356
P1476
Pharmacogenetic considerations ...... and kidney transplant patients
@en
P2093
Alessio Provenzani
Ambra Provenzani
Andrew Santeusanio
Carlo Polidori
Erin Mathis
Giovanni Vizzini
Manuela Labbozzetta
Monica Notarbartolo
Natale D'Alessandro
Paola Poma
P2860
P304
P356
10.3748/WJG.V19.I48.9156
P407
P577
2013-12-01T00:00:00Z